Viamet reported on 12 February 2015 the start of a randomized, double-blind, placebo-controlled phase IIb trial in the USA to assess VT 1161 in approximately 200 patients with recurrent vulvovaginal candidiasis (RVVC). Two dose levels ofVT 1161, administered once weekly at 11 or 23 weeks after a one-week loading-dose period, will be evaluated. Prevention of acute episodes of vulvovaginal candidiasis through week 48 of the trial is the primary outcome measure.VT 1161, a small molecule lanosterol demethylase (CYP51) inhibitor, was discovered using Viamet's proprietary METALLOPHILE technology. The agent has been evaluated in two phase IIa in trials in the treatment of RVVC and moderate-to-severe interdigital tinea pedis, respectively.
Monday, February 16, 2015
New antifungal drugs